

(12) **United States Patent**  
**Steward et al.**

(10) **Patent No.:** **US 11,559,437 B2**  
(45) **Date of Patent:** **Jan. 24, 2023**

(54) **MULTI-LAYERED WOUND DRESSING AND METHOD OF MANUFACTURE**

(71) Applicant: **Smith & Nephew PLC**, Watford (GB)

(72) Inventors: **Daniel Lee Steward**, Hull (GB);  
**Emma Cole**, Hull (GB); **Hannah Bailey Sidebottom**, Lincoln (GB); **Neil Patrick**, Hull (GB)

(73) Assignee: **Smith & Nephew PLC**, Watford (GB)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 848 days.

(21) Appl. No.: **16/345,196**

(22) PCT Filed: **Oct. 24, 2017**

(86) PCT No.: **PCT/EP2017/077154**

§ 371 (c)(1),  
(2) Date: **Apr. 25, 2019**

(87) PCT Pub. No.: **WO2018/077872**

PCT Pub. Date: **May 3, 2018**

(65) **Prior Publication Data**  
US 2019/0274889 A1 Sep. 12, 2019

(30) **Foreign Application Priority Data**  
Oct. 28, 2016 (GB) ..... 1618298

(51) **Int. Cl.**  
**A61F 13/00** (2006.01)  
**A61F 13/02** (2006.01)  
(Continued)

(52) **U.S. Cl.**  
CPC .. **A61F 13/00029** (2013.01); **A61F 13/00038** (2013.01); **A61F 13/00068** (2013.01); **A61F 13/0226** (2013.01); **A61F 13/0286** (2013.01); **A61M 1/90** (2021.05); **A61F 2013/00097** (2013.01); **A61F 2013/00548** (2013.01);  
(Continued)

(58) **Field of Classification Search**  
None  
See application file for complete search history.

(56) **References Cited**  
U.S. PATENT DOCUMENTS  
730,062 A 6/1903 Widmer  
1,052,274 A 2/1913 Purdy  
(Continued)


FOREIGN PATENT DOCUMENTS  
CN 101002707 A 7/2007  
EP 0053936 A2 6/1982  
(Continued)

OTHER PUBLICATIONS  
Brief Communication—Letter from the Proprietor of the Patent dated Jun. 16, 2020, for the Opposition of European Patent No. EP2731564, 19 pages.  
(Continued)

*Primary Examiner* — Kim M Lewis  
(74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson & Bear LLP

(57) **ABSTRACT**  
A multi-layered wound dressing including a fibrous absorbent layer for absorbing exudate from a wound site. The wound dressing also includes a support layer configured to reduce shrinkage of at least a portion of the wound dressing.

**20 Claims, 5 Drawing Sheets**



(51)	<b>Int. Cl.</b>		5,431,643 A	7/1995	Ouellette et al.
	<i>A61M 1/00</i>	(2006.01)	5,437,651 A	8/1995	Todd et al.
	<i>A61F 13/15</i>	(2006.01)	5,447,492 A	9/1995	Cartmell et al.
(52)	<b>U.S. Cl.</b>		5,454,800 A	10/1995	Hirt et al.
	CPC .....	<i>A61F 2013/00608</i> (2013.01); <i>A61F</i>	5,456,660 A	10/1995	Reich et al.
		<i>2013/1591</i> (2013.01)	5,465,735 A	11/1995	Patel
			5,470,326 A	11/1995	Dabi et al.
			H1511 H	12/1995	Chappell et al.
(56)	<b>References Cited</b>		5,480,377 A	1/1996	Cartmell et al.
	<b>U.S. PATENT DOCUMENTS</b>		5,486,167 A	1/1996	Dragoo et al.
			5,487,736 A	1/1996	Van Phan
			5,497,788 A	3/1996	Inman et al.
	2,054,768 A	9/1936 Gale, Jr. et al.	5,500,270 A	3/1996	Langdon et al.
	2,233,209 A	2/1941 Herzog	5,505,719 A	4/1996	Cohen et al.
	2,280,506 A	4/1942 Betts	5,509,914 A	4/1996	Osborn, III
	2,682,873 A	7/1954 Idnis et al.	5,514,120 A	5/1996	Johnston et al.
	2,905,174 A	9/1959 Smith	5,520,629 A	5/1996	Heinecke et al.
	2,992,644 A	7/1961 Plantinga et al.	5,525,407 A	6/1996	Yang
	3,043,301 A	7/1962 Plantinga et al.	5,536,264 A	7/1996	Hsueh et al.
	3,156,242 A	11/1964 Crowe, Jr. et al.	5,538,500 A	7/1996	Peterson
	3,204,277 A	9/1965 Sierik et al.	H1585 H	8/1996	Ahr
	3,301,429 A	1/1967 McClain	5,545,155 A	8/1996	Hseih et al.
	3,416,524 A	12/1968 Meier	5,549,584 A	8/1996	Gross
	3,529,597 A	9/1970 Fuzak et al.	5,549,589 A	8/1996	Horney et al.
	3,616,154 A	10/1971 Dow et al.	5,562,107 A	10/1996	Lavender et al.
	3,687,136 A	8/1972 Carmody	5,562,646 A	10/1996	Goldman et al.
	4,212,296 A	7/1980 Schaar	5,562,650 A	10/1996	Everett et al.
	4,649,909 A	3/1987 Thompson	5,579,765 A	12/1996	Cox et al.
	4,798,603 A	1/1989 Meyer et al.	5,591,148 A	1/1997	McFall et al.
	4,834,735 A	5/1989 Alemany et al.	5,591,149 A	1/1997	Cree et al.
	4,846,164 A	7/1989 Martz	5,593,395 A	1/1997	Martz
	4,901,714 A	2/1990 Jensen	5,603,707 A	2/1997	Trombetta et al.
	4,968,181 A	11/1990 Goldman	5,603,946 A	2/1997	Constantine
	4,973,325 A	11/1990 Sherrod et al.	5,609,588 A	3/1997	DiPalma et al.
	4,988,344 A	1/1991 Reising et al.	5,613,960 A	3/1997	Mizutani
	4,988,345 A	1/1991 Reising	5,614,283 A	3/1997	Potnis et al.
	5,018,515 A	5/1991 Gilman	5,614,295 A	3/1997	Quincy, III et al.
	5,021,050 A	6/1991 Iskra	5,628,736 A	5/1997	Thompson
	5,037,409 A	8/1991 Chen et al.	5,632,731 A	5/1997	Patel
	5,065,600 A	11/1991 Byles	H1657 H	6/1997	Hammons et al.
	5,115,801 A	5/1992 Cartmell et al.	5,634,915 A	6/1997	Osterdahl
	5,124,197 A	6/1992 Bernardin et al.	5,636,643 A	6/1997	Argenta et al.
	5,149,334 A	9/1992 Lahrman et al.	5,637,080 A	6/1997	Geng
	5,151,091 A	9/1992 Glaug et al.	5,643,238 A	7/1997	Baker
	5,160,328 A	11/1992 Cartmell et al.	5,645,081 A	7/1997	Argenta et al.
	5,171,391 A	12/1992 Chmielewski et al.	5,648,142 A	7/1997	Phillips
	5,175,046 A	12/1992 Nguyen	5,649,915 A	7/1997	Chauvette et al.
	5,176,663 A	1/1993 Svedman et al.	5,649,916 A	7/1997	DiPalma et al.
	5,197,945 A	3/1993 Cole et al.	5,662,599 A	9/1997	Reich et al.
	5,217,445 A	6/1993 Young et al.	5,665,082 A	9/1997	Boulanger
	5,236,427 A	8/1993 Hamajima et al.	5,669,895 A	9/1997	Murakami et al.
	5,242,435 A	9/1993 Murji et al.	5,675,079 A	10/1997	Gilman et al.
	5,257,982 A	11/1993 Cohen et al.	5,683,354 A	11/1997	Levy
	5,271,987 A	12/1993 Iskra	5,700,254 A	12/1997	McDowall et al.
	5,281,208 A	1/1994 Thompson et al.	5,702,356 A	12/1997	Hathman
	5,294,478 A	3/1994 Wanek et al.	5,704,905 A	1/1998	Jensen et al.
	5,296,290 A	3/1994 Brassington	5,713,384 A	2/1998	Roach et al.
	5,314,743 A	5/1994 Meirowitz et al.	5,713,842 A	2/1998	Kay
	5,318,554 A	6/1994 Young et al.	5,716,703 A	2/1998	Payne
	5,330,456 A	7/1994 Robinson	5,728,084 A	3/1998	Palumbo et al.
	5,336,219 A	8/1994 Krantz	5,728,085 A	3/1998	Widlund et al.
	5,342,336 A	8/1994 Meirowitz et al.	5,733,273 A	3/1998	Ahr
	5,348,547 A	9/1994 Payne et al.	5,752,945 A	5/1998	Mosley et al.
	5,354,261 A	10/1994 Clark et al.	5,762,641 A	6/1998	Bewick-Sonntag et al.
	5,356,405 A	10/1994 Thompson et al.	5,788,684 A	8/1998	Abuto et al.
	5,360,420 A	11/1994 Cook et al.	5,801,107 A	9/1998	Everhart et al.
	5,364,381 A	11/1994 Soga et al.	5,810,798 A	9/1998	Finch et al.
	5,364,382 A	11/1994 Latimer et al.	5,817,081 A	10/1998	LaVon et al.
	5,366,451 A	11/1994 Levesque	5,820,578 A	10/1998	Johansen
	5,368,909 A	11/1994 Langdon et al.	5,827,213 A	10/1998	Jensen
	5,368,926 A	11/1994 Thompson et al.	5,827,254 A	10/1998	Trombetta et al.
	5,374,260 A	12/1994 Lemay et al.	5,830,202 A	11/1998	Bogdanski et al.
	5,380,294 A	1/1995 Persson	5,837,627 A	11/1998	Halabisky et al.
	5,382,245 A	1/1995 Thompson et al.	5,840,052 A	11/1998	Johns
	5,387,208 A	2/1995 Ashton et al.	5,843,025 A	12/1998	Shaari
	5,387,209 A	2/1995 Yamamoto et al.	5,843,064 A	12/1998	Koczab
	5,397,316 A	3/1995 LaVon et al.	5,855,572 A	1/1999	Schmidt
	5,401,267 A	3/1995 Couture-Dorschner et al.	5,865,822 A	2/1999	Hamajima et al.
	5,425,725 A	6/1995 Tanzer et al.	5,865,824 A	2/1999	Chen et al.



(56)

References Cited

U.S. PATENT DOCUMENTS

5,873,867 A	2/1999	Coles et al.	6,776,769 B2	8/2004	Smith
5,877,097 A	3/1999	West et al.	6,783,837 B1	8/2004	Creagan et al.
5,891,120 A	4/1999	Chmielewski	6,787,682 B2	9/2004	Gilman
5,895,379 A	4/1999	Litchholt et al.	6,835,192 B1	12/2004	Guidotti et al.
5,897,541 A	4/1999	Uitenbroek et al.	6,838,589 B2	1/2005	Liedtke et al.
5,916,507 A	6/1999	Dabi et al.	6,841,715 B2	1/2005	Roberts
5,925,026 A	7/1999	Arteman et al.	6,878,647 B1 *	4/2005	Rezai ..... B32B 37/144 442/18
5,931,823 A	8/1999	Stokes et al.	6,936,037 B2	8/2005	Bubb et al.
5,938,995 A	8/1999	Koltisko, Jr. et al.	6,951,553 B2	10/2005	Bubb et al.
5,941,863 A	8/1999	Guidotti et al.	6,960,181 B2	11/2005	Stevens
5,947,945 A	9/1999	Cree et al.	6,998,511 B2	2/2006	Worthley
5,951,535 A	9/1999	Fujiwara et al.	7,004,915 B2	2/2006	Boynton et al.
5,961,506 A	10/1999	Guidotti et al.	7,049,478 B1	5/2006	Smith
5,968,027 A	10/1999	Cole et al.	7,108,683 B2	9/2006	Zamierowski
5,989,478 A	11/1999	Ouellette et al.	7,112,712 B1	9/2006	Ancell
6,022,610 A	2/2000	Phan et al.	7,118,545 B2	10/2006	Boyde
6,037,518 A	3/2000	Guidotti et al.	7,122,023 B1	10/2006	Hinoki
6,040,493 A	3/2000	Cooke et al.	7,122,712 B2	10/2006	Lutri et al.
6,060,638 A	5/2000	Paul et al.	7,183,345 B2	2/2007	Kim
6,068,620 A	5/2000	Chmielewski	7,195,624 B2	3/2007	Lockwood et al.
6,071,267 A	6/2000	Zamierowski	7,294,751 B2	11/2007	Propp et al.
6,075,177 A	6/2000	Bahia et al.	7,294,752 B1	11/2007	Propp
6,077,526 A	6/2000	Scully et al.	7,381,859 B2	6/2008	Hunt et al.
6,096,015 A	8/2000	Yeo et al.	7,429,689 B2	9/2008	Chen et al.
6,103,953 A	8/2000	Cree et al.	7,438,705 B2	10/2008	Karpowicz et al.
6,103,954 A	8/2000	Grondin et al.	7,476,205 B2	1/2009	Erdmann
6,107,539 A	8/2000	Palumbo et al.	7,507,870 B2	3/2009	Nielsen et al.
6,124,520 A	9/2000	Roberts	7,511,187 B2	3/2009	Kelly
6,124,521 A	9/2000	Roberts	7,563,940 B2	7/2009	Kurata
6,127,595 A	10/2000	Makoui et al.	7,569,742 B2	8/2009	Haggstrom et al.
6,142,982 A	11/2000	Hunt et al.	7,576,256 B2	8/2009	Bjornberg et al.
6,168,849 B1	1/2001	Braverman et al.	7,605,298 B2	10/2009	Bechert et al.
6,191,340 B1	2/2001	Carlucci et al.	7,615,036 B2	11/2009	Joshi et al.
6,206,865 B1	3/2001	Chen et al.	7,622,629 B2	11/2009	Aali
6,223,383 B1	5/2001	Vanputten	7,645,269 B2	1/2010	Zamierowski
6,235,966 B1	5/2001	Magnusson et al.	7,676,257 B2	3/2010	Suryanarayanan et al.
6,264,776 B1	7/2001	DiPalma	7,708,724 B2	5/2010	Weston
6,294,710 B1	9/2001	Schmidt et al.	7,722,582 B2	5/2010	Lina et al.
6,297,423 B1	10/2001	Schoenfeldt et al.	7,723,561 B2	5/2010	Propp
6,344,036 B1	2/2002	Ivansson	7,749,531 B2	7/2010	Booher
6,345,623 B1	2/2002	Heaton et al.	7,759,537 B2	7/2010	Bishop et al.
6,362,390 B1	3/2002	Carlucci et al.	7,759,539 B2	7/2010	Shaw et al.
6,369,292 B1	4/2002	Strack et al.	7,775,998 B2	8/2010	Riesinger
6,372,952 B1	4/2002	Lash et al.	7,776,028 B2	8/2010	Miller et al.
6,403,857 B1	6/2002	Gross et al.	7,779,625 B2	8/2010	Joshi et al.
6,468,295 B2	10/2002	Augustine et al.	7,794,438 B2	9/2010	Henley et al.
6,497,689 B1	12/2002	Schmidt et al.	7,838,719 B2	11/2010	Hilton, Jr.
6,506,175 B1	1/2003	Goldstein	7,838,723 B1	11/2010	Schmidt et al.
6,506,960 B1	1/2003	Young et al.	7,909,805 B2	3/2011	Weston
6,521,813 B1	2/2003	Chihani	7,922,703 B2	4/2011	Riesinger
6,528,696 B1	3/2003	Ireland	7,935,066 B2	5/2011	Shives et al.
6,534,149 B1	3/2003	Daley et al.	7,959,624 B2	6/2011	Riesinger
6,545,194 B1	4/2003	Schmidt et al.	7,964,766 B2	6/2011	Blott et al.
6,551,295 B1	4/2003	Schmidt et al.	7,976,519 B2	7/2011	Bubb et al.
6,570,057 B1	5/2003	Schmidt et al.	7,988,673 B2	8/2011	Wright et al.
6,570,058 B1	5/2003	Fuchs et al.	8,021,347 B2	9/2011	Vitaris et al.
6,573,424 B1	6/2003	Raidel et al.	8,062,272 B2	11/2011	Weston
6,586,653 B2	7/2003	Graeme, III et al.	8,092,436 B2	1/2012	Christensen
6,610,898 B1	8/2003	Magnusson et al.	8,147,468 B2	4/2012	Barta et al.
6,610,903 B1	8/2003	Latimer et al.	8,152,785 B2	4/2012	Vitaris
6,613,028 B1	9/2003	Daley et al.	8,162,907 B2	4/2012	Heagle
6,613,953 B1	9/2003	Altura	8,168,848 B2	5/2012	Lockwood et al.
6,613,955 B1	9/2003	Lindsay et al.	8,188,331 B2	5/2012	Barta et al.
6,626,891 B2	9/2003	Ohmstede	8,202,261 B2	6/2012	Kazala, Jr. et al.
6,630,611 B1	10/2003	Malowaniec	8,212,101 B2	7/2012	Propp
6,648,862 B2	11/2003	Watson	8,241,261 B2	8/2012	Randolph et al.
6,664,439 B1	12/2003	Arndt et al.	8,246,606 B2	8/2012	Stevenson et al.
6,683,229 B1	1/2004	Ehrnsperger et al.	8,252,971 B2	8/2012	Aali et al.
6,685,681 B2	2/2004	Lockwood et al.	8,314,283 B2	11/2012	Kingsford et al.
6,706,940 B2	3/2004	Worthley	8,328,858 B2	12/2012	Barsky et al.
6,719,742 B1	4/2004	McCormack et al.	8,372,050 B2	2/2013	Jaeb et al.
6,727,403 B1	4/2004	Ehrnsperger et al.	8,376,972 B2	2/2013	Fleischmann
6,752,794 B2	6/2004	Lockwood et al.	8,382,731 B2	2/2013	Johannison
6,762,337 B2	7/2004	Boukanov et al.	8,403,899 B2	3/2013	Sherman
6,764,459 B1	7/2004	Donaldson	8,404,921 B2	3/2013	Lee et al.
			8,425,478 B2	4/2013	Olson
			8,444,611 B2	5/2013	Wilkes et al.
			8,449,508 B2	5/2013	Coulthard et al.



(56)

References Cited

U.S. PATENT DOCUMENTS

8,481,804 B2 *	7/2013	Timothy .....	A61F 13/00021 602/53	2003/0150551 A1	8/2003	Baker	
				2003/0157857 A1	8/2003	Cook et al.	
				2003/0171729 A1	9/2003	Kaun et al.	
				2003/0180341 A1	9/2003	Gooch et al.	
				2003/0190854 A1 *	10/2003	Stagray .....	B32B 37/1284 442/381
8,513,481 B2	8/2013	Gergely et al.		2003/0199800 A1	10/2003	Levin	
8,535,296 B2	9/2013	Blott et al.		2003/0208175 A1	11/2003	Gross et al.	
8,545,466 B2	10/2013	Andresen et al.		2003/0212359 A1	11/2003	Butler	
8,663,198 B2	3/2014	Buan et al.		2003/0225383 A1	12/2003	Glaug et al.	
8,680,360 B2	3/2014	Greener et al.		2004/0019338 A1	1/2004	Litvay et al.	
8,708,998 B2	4/2014	Weston et al.		2004/0019339 A1	1/2004	Ranganathan et al.	
8,715,256 B2	5/2014	Greener		2004/0019340 A1	1/2004	McBride	
8,722,961 B2	5/2014	Vinton et al.		2004/0019342 A1	1/2004	Nagasuna et al.	
8,764,732 B2	7/2014	Hartwell		2004/0024102 A1 *	2/2004	Hayes .....	B32B 7/12 524/425
8,791,316 B2	7/2014	Greener					
8,795,247 B2	8/2014	Bennett et al.		2004/0024375 A1	2/2004	Litvay	
8,801,685 B2	8/2014	Armstrong et al.		2004/0033750 A1	2/2004	Everett et al.	
8,814,842 B2	8/2014	Coulthard et al.		2004/0049146 A1	3/2004	Kolte et al.	
8,843,327 B2	9/2014	Vernon-Harcourt et al.		2004/0054343 A1	3/2004	Barnett et al.	
8,916,742 B2	12/2014	Smith		2004/0054344 A1	3/2004	Roettger et al.	
8,986,270 B2	3/2015	Johannison et al.		2004/0065420 A1	4/2004	Graef et al.	
9,033,942 B2	5/2015	Vess		2004/0076662 A1	4/2004	Riesinger	
9,061,095 B2	6/2015	Adie et al.		2004/0078016 A1	4/2004	Baker	
9,220,822 B2	12/2015	Hartwell		2004/0087927 A1	5/2004	Suzuki	
9,254,353 B2	2/2016	Locke et al.		2004/0111074 A1	6/2004	Eliasson	
9,265,665 B2	2/2016	Robinson et al.		2004/0138602 A1	7/2004	Rossen	
9,579,411 B2	2/2017	Addison et al.		2004/0177935 A1	9/2004	Hamed et al.	
2001/0000795 A1	5/2001	Bolian, II et al.		2004/0181199 A1	9/2004	Moberg-Alehammar et al.	
2001/0016985 A1	8/2001	Insley et al.		2004/0204696 A1	10/2004	Chen	
2001/0018308 A1	8/2001	Quick et al.		2004/0230173 A1	11/2004	Barge et al.	
2001/0027302 A1	10/2001	Glaug et al.		2004/0230184 A1	11/2004	Babusik et al.	
2001/0027305 A1	10/2001	Raidel et al.		2004/0241214 A1	12/2004	Kirkwood et al.	
2001/0044610 A1	11/2001	Kim et al.		2004/0243042 A1	12/2004	Lipman	
2001/0051178 A1	12/2001	Blatchford et al.		2004/0243080 A1	12/2004	Baer	
2001/0053904 A1	12/2001	Abuto		2004/0243081 A1	12/2004	Suzuki et al.	
2002/0007167 A1	1/2002	Dan et al.		2004/0253894 A1	12/2004	Fell et al.	
2002/0007169 A1	1/2002	Graef et al.		2004/0254552 A1	12/2004	Mangold	
2002/0019602 A1	2/2002	Geng		2005/0008825 A1	1/2005	Casey et al.	
2002/0019614 A1	2/2002	Woon et al.		2005/0013992 A1	1/2005	Azad et al.	
2002/0026166 A1	2/2002	Graef et al.		2005/0015036 A1	1/2005	Lutri et al.	
2002/0034914 A1	3/2002	De Leon et al.		2005/0049566 A1	3/2005	Vukos et al.	
2002/0035354 A1	3/2002	Mirle et al.		2005/0079361 A1	4/2005	Hamed et al.	
2002/0062113 A1	5/2002	Thomas et al.		2005/0096616 A1	5/2005	Arora et al.	
2002/0064639 A1	5/2002	Rearick et al.		2005/0112979 A1	5/2005	Sawyer et al.	
2002/0087136 A1	7/2002	Widlund		2005/0119631 A1	6/2005	Giloh et al.	
2002/0090511 A1	7/2002	Smith et al.		2005/0136773 A1	6/2005	Yahiaoui et al.	
2002/0110672 A1	8/2002	Muratore-Pallatino et al.		2005/0165371 A1	7/2005	Giacometti	
2002/0123728 A1	9/2002	Graef et al.		2005/0215965 A1	9/2005	Schmidt et al.	
2002/0133132 A1	9/2002	Copat et al.		2005/0215967 A1	9/2005	Toro et al.	
2002/0150678 A1	10/2002	Cramer et al.		2005/0222547 A1	10/2005	Beruda et al.	
2002/0165509 A1	11/2002	Baer et al.		2005/0228353 A1	10/2005	Thomas	
2002/0176964 A1	11/2002	Koslow		2005/0261649 A1	11/2005	Cohen	
2002/0177831 A1	11/2002	Daley et al.		2005/0267429 A1	12/2005	Cohen	
2002/0180092 A1	12/2002	Abba et al.		2006/0003604 A1	1/2006	Angerpointner	
2002/0183704 A1	12/2002	Fields et al.		2006/0009744 A1	1/2006	Erdman et al.	
2003/0009122 A1	1/2003	Veras		2006/0020250 A1	1/2006	Chester et al.	
2003/0045707 A1	3/2003	West et al.		2006/0058750 A1	3/2006	Di Girolamo et al.	
2003/0045825 A1	3/2003	Etheredge, III		2006/0069366 A1	3/2006	Cole	
2003/0050617 A1	3/2003	Chen et al.		2006/0069367 A1	3/2006	Waksmundzki et al.	
2003/0069563 A1	4/2003	Johnson		2006/0069375 A1	3/2006	Waksmundzki et al.	
2003/0070780 A1	4/2003	Chen et al.		2006/0122548 A1	6/2006	Abrams	
2003/0073967 A1	4/2003	Wahlstrom et al.		2006/0122572 A1	6/2006	Suarez	
2003/0088229 A1	5/2003	Baker et al.		2006/0153904 A1	7/2006	Smith et al.	
2003/0088231 A1	5/2003	Yoshimasa et al.		2006/0161122 A1	7/2006	Erdman et al.	
2003/0093044 A1	5/2003	Wahlstrom et al.		2006/0178650 A1	8/2006	Hakansson et al.	
2003/0097101 A1	5/2003	Schmidt et al.		2006/0184147 A1	8/2006	Hamed	
2003/0097105 A1	5/2003	Chen et al.		2006/0206047 A1	9/2006	Lampe et al.	
2003/0097113 A1	5/2003	Molee		2006/0206073 A1	9/2006	Crane et al.	
2003/0105442 A1	6/2003	Johnston et al.		2006/0206074 A1	9/2006	Bernal et al.	
2003/0114816 A1	6/2003	Underhill et al.		2006/0241542 A1	10/2006	Gudnason et al.	
2003/0114818 A1	6/2003	Benecke et al.		2006/0282028 A1	12/2006	Howard et al.	
2003/0114821 A1	6/2003	Underhill et al.		2007/0003604 A1	1/2007	Jones	
2003/0120249 A1	6/2003	Wulz et al.		2007/0021697 A1	1/2007	Ginther et al.	
2003/0121588 A1	7/2003	Pargass et al.		2007/0073254 A1	3/2007	Ponomarenko et al.	
2003/0124311 A1	7/2003	Cree et al.		2007/0078467 A1	4/2007	Mullen	
2003/0134559 A1	7/2003	Delzer et al.		2007/0100308 A1	5/2007	Miyairi	
2003/0135174 A1	7/2003	Benecke et al.		2007/0142804 A1	6/2007	Bernard	
2003/0135177 A1	7/2003	Baker		2007/0167096 A1	7/2007	Scott	



(56)

References Cited

U.S. PATENT DOCUMENTS

2007/0167884 A1 7/2007 Mangrum et al.  
 2007/0224903 A1 9/2007 Chakravarty et al.  
 2007/0225663 A1 9/2007 Watt et al.  
 2007/0254550 A1 11/2007 Hamed et al.  
 2007/0270070 A1 11/2007 Hamed  
 2007/0282236 A1 12/2007 LaGreca  
 2008/0004581 A1 1/2008 Babusik et al.  
 2008/0015532 A1 1/2008 Waksmundzki  
 2008/0058691 A1 3/2008 Sorensen  
 2008/0082075 A1 4/2008 Morrell-Schwartz  
 2008/0090050 A1 4/2008 Seyler et al.  
 2008/0091152 A1 4/2008 Asherman  
 2008/0114317 A1 5/2008 Seyler  
 2008/0119586 A1 5/2008 Byerly et al.  
 2008/0147024 A1 6/2008 Potts et al.  
 2008/0167592 A1 7/2008 Greer  
 2008/0243100 A1 10/2008 Wu et al.  
 2008/0254103 A1 10/2008 Harris et al.  
 2008/0255533 A1 10/2008 Wu et al.  
 2008/0275409 A1 11/2008 Kane et al.  
 2008/0312621 A1 12/2008 Hundorf et al.  
 2008/0312622 A1 12/2008 Hundorf et al.  
 2009/0062760 A1 3/2009 Wright et al.  
 2009/0065014 A1 3/2009 Nagata  
 2009/0076472 A1 3/2009 Goldwasser et al.  
 2009/0112175 A1 4/2009 Bissah et al.  
 2009/0204087 A1 8/2009 Herfert et al.  
 2009/0216168 A1 8/2009 Eckstein  
 2009/0227935 A1 9/2009 Zanella et al.  
 2009/0227969 A1 9/2009 Jaeb et al.  
 2009/0240218 A1 9/2009 Braga et al.  
 2009/0281471 A1 11/2009 Iwahashi et al.  
 2009/0293887 A1 12/2009 Wilkes et al.  
 2009/0299251 A1 12/2009 Buan  
 2009/0299255 A1 12/2009 Kazala, Jr. et al.  
 2009/0299340 A1 12/2009 Kazala, Jr. et al.  
 2010/0010461 A1 1/2010 Herfert et al.  
 2010/0030171 A1 2/2010 Canada et al.  
 2010/0036334 A1 2/2010 Heagle et al.  
 2010/0036342 A1 2/2010 Carlucci et al.  
 2010/0048072 A1 2/2010 Kauschke et al.  
 2010/0055158 A1 3/2010 Vitaris et al.  
 2010/0069858 A1 3/2010 Olson  
 2010/0084074 A1 4/2010 McClernon et al.  
 2010/0087767 A1 4/2010 McNeil  
 2010/0106120 A1 4/2010 Holm  
 2010/0106121 A1 4/2010 Holm  
 2010/0121286 A1 5/2010 Locke et al.  
 2010/0121298 A1 5/2010 Seyler et al.  
 2010/0122417 A1 5/2010 Vrzalik et al.  
 2010/0125234 A1 5/2010 Smith  
 2010/0125258 A1 5/2010 Coulthard et al.  
 2010/0168695 A1 7/2010 Robles et al.  
 2010/0179463 A1 7/2010 Greener et al.  
 2010/0217177 A1 8/2010 Cali et al.  
 2010/0256545 A1 10/2010 Aali et al.  
 2010/0256584 A1 10/2010 Litvay  
 2010/0256586 A1 10/2010 Bergstrom et al.  
 2010/0262091 A1 10/2010 Larsson  
 2010/0305526 A1 12/2010 Robinson et al.  
 2010/0318047 A1 12/2010 Ducker et al.  
 2010/0318052 A1 12/2010 Ha et al.  
 2010/0324516 A1 12/2010 Braga et al.  
 2011/0004172 A1 1/2011 Eckstein et al.  
 2011/0052664 A1 3/2011 Tennican et al.  
 2011/0054422 A1 3/2011 Locke et al.  
 2011/0059329 A1 3/2011 Dobrawa et al.  
 2011/0060303 A1 3/2011 Bissah et al.  
 2011/0092927 A1 4/2011 Wilkes et al.  
 2011/0098621 A1 4/2011 Fabo et al.  
 2011/0106030 A1 5/2011 Scholz  
 2011/0112492 A1 5/2011 Bharti et al.  
 2011/0125119 A1 5/2011 Weismantel et al.  
 2011/0137222 A1 6/2011 Masini  
 2011/0152813 A1 6/2011 Ellingson

2011/0178375 A1 7/2011 Forster  
 2011/0183109 A1 7/2011 Seyler et al.  
 2011/0184364 A1 7/2011 Biggs et al.  
 2011/0184370 A1 7/2011 Seyler et al.  
 2011/0208145 A1 8/2011 Zhang et al.  
 2011/0213286 A1 9/2011 Riesinger  
 2011/0218509 A1 9/2011 Dontas  
 2011/0223413 A1 9/2011 Herfert et al.  
 2011/0224631 A1 9/2011 Simmons et al.  
 2011/0238026 A1 9/2011 Zhang et al.  
 2011/0245788 A1 10/2011 Marquez Canada  
 2011/0247636 A1 10/2011 Pollack  
 2011/0257572 A1 10/2011 Locke et al.  
 2011/0268932 A1 11/2011 Catalan et al.  
 2012/0004632 A1 1/2012 Zhang et al.  
 2012/0045639 A1 2/2012 Whitmore et al.  
 2012/0053547 A1 3/2012 Schroeder et al.  
 2012/0071848 A1 3/2012 Zhang et al.  
 2012/0095426 A1 4/2012 Visscher et al.  
 2012/0101465 A1 4/2012 McGuire, Jr.  
 2012/0123311 A1 5/2012 Weidemann-Hendrickson et al.  
 2012/0130332 A1 5/2012 Cotton et al.  
 2012/0136329 A1 5/2012 Carney  
 2012/0143158 A1 6/2012 Yang et al.  
 2012/0172778 A1 7/2012 Rastegar et al.  
 2012/0197229 A1 8/2012 Buan et al.  
 2012/0203145 A1 8/2012 Nilsson  
 2012/0220968 A1 8/2012 Confalone et al.  
 2012/0232502 A1 9/2012 Lowing  
 2012/0238932 A1 9/2012 Atteia et al.  
 2012/0283529 A1 11/2012 Marchand et al.  
 2012/0302440 A1 11/2012 Theliander et al.  
 2012/0308780 A1 12/2012 Rottger et al.  
 2012/0310186 A1 12/2012 Moghe et al.  
 2012/0310197 A1 12/2012 Thomas  
 2012/0330252 A1 12/2012 Stokes et al.  
 2012/0330253 A1 12/2012 Robinson et al.  
 2013/0012902 A1 1/2013 Rovaniemi  
 2013/0197460 A1\* 8/2013 Shaw ..... A61F 13/539  
 2014/0114268 A1 4/2014 Auguste et al.  
 2015/0159066 A1 6/2015 Hartwell et al.  
 2015/0174304 A1 6/2015 Askem et al.  
 2018/0125720 A1 5/2018 Pigg  
 2019/0110932 A1 4/2019 Mumby et al.  
 2019/0216651 A1 7/2019 Vitaris et al.

FOREIGN PATENT DOCUMENTS

EP 0147119 A2 7/1985  
 EP 0541251 A1 5/1993  
 EP 0619105 A1 10/1994  
 EP 0748894 A2 12/1996  
 EP 0875224 A1 11/1998  
 EP 0941726 A1 9/1999  
 EP 1013290 A1 6/2000  
 EP 1048278 A2 11/2000  
 EP 1066809 A2 1/2001  
 EP 1312328 A2 5/2003  
 EP 1452156 A1 9/2004  
 EP 1 314 410 2/2010  
 EP 2161011 A1 3/2010  
 EP 2366721 A1 9/2011  
 EP 2659915 B1 10/2015  
 GB 2272917 A 6/1994  
 GB 2355228 A 4/2001  
 GB 2435422 A 8/2007  
 GB 2435423 A 8/2007  
 GB 2489947 A 10/2012  
 GB 2525494 10/2015  
 JP 2001145655 A 5/2001  
 JP 2007275185 A 10/2007  
 JP 2008119497 A 5/2008  
 WO WO-9111161 A1 8/1991  
 WO WO-9111162 A1 8/1991  
 WO WO-9301778 A1 2/1993  
 WO WO-9301781 A1 2/1993  
 WO WO-9311726 A1 6/1993  
 WO WO-9513042 A1 5/1995



(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	WO-9513779	A1	5/1995
WO	WO-9514451	A1	6/1995
WO	WO-9516424	A1	6/1995
WO	WO-9607783	A1	3/1996
WO	WO-9621410	A1	7/1996
WO	WO-9711658	A1	4/1997
WO	WO-9714384	A1	4/1997
WO	WO-9820916	A1	5/1998
WO	WO-9822279	A1	5/1998
WO	WO-9904830	A1	2/1999
WO	WO-9939671	A1	8/1999
WO	WO-9945876	A1	9/1999
WO	WO-9945878	A1	9/1999
WO	WO-9956687	A1	11/1999
WO	WO-0000016	A1	1/2000
WO	WO-0000127	A1	1/2000
WO	WO-0000129	A1	1/2000
WO	WO-0000130	A1	1/2000
WO	WO-0000131	A1	1/2000
WO	WO-0040190	A1	7/2000
WO	WO-0042957	A1	7/2000
WO	WO-0059438	A1	10/2000
WO	WO-0172251	A1	10/2001
WO	WO-0190465	A2	11/2001
WO	WO-0217840	A1	3/2002
WO	WO-0224132	A2	3/2002
WO	WO-0226180	A1	4/2002
WO	WO-0238096	A2	5/2002
WO	WO-02076379	A2	10/2002
WO	WO-03057307	A1	7/2003
WO	WO-03073971	A2	9/2003
WO	WO-2004043321	A1	5/2004
WO	WO-2004073566	A1	9/2004
WO	WO-2004098474	A1	11/2004
WO	WO-2006105305	A1	10/2006
WO	WO-2007035038	A1	3/2007
WO	WO-2007040606	A2	4/2007
WO	WO-2007077214	A1	7/2007
WO	WO-2007077216	A1	7/2007
WO	WO-2007082538	A1	7/2007
WO	WO-2007116347	A2	10/2007
WO	WO-2007134516	A1	11/2007
WO	WO-2008049277	A1	5/2008
WO	WO-2008131895	A1	11/2008
WO	WO-2009019227	A2	2/2009
WO	WO-2009019229	A2	2/2009
WO	WO-2009103031	A1	8/2009
WO	WO-2009152021	A2	12/2009
WO	WO-2010032951	A2	3/2010
WO	WO-2010072395	A1	7/2010
WO	WO-2010082872	A1	7/2010
WO	WO-2010089448	A1	8/2010
WO	WO-2010139926	A1	12/2010

WO	WO-2011019476	A1	2/2011
WO	WO-2011023275	A1	3/2011
WO	WO-2011023650	A1	3/2011
WO	WO 2011/057240		5/2011
WO	WO-2011058311	A1	5/2011
WO	WO-2011063818	A1	6/2011
WO	WO-2011113728	A1	9/2011
WO	WO-2011128651	A1	10/2011
WO	WO-2011152368	A1	12/2011
WO	WO-2012009370	A2	1/2012
WO	WO-2012035787	A1	3/2012
WO	WO-2012074512	A1	6/2012
WO	WO-2012146656	A1	11/2012
WO	WO-2012150235	A1	11/2012
WO	WO-2012168298	A1	12/2012
WO	WO-2013014317	A1	1/2013
WO	WO-2013029652	A1	3/2013
WO	WO-2013060732	A1	5/2013
WO	WO-2013175306	A2	11/2013
WO	WO-2014003957	A1	1/2014
WO	WO 2017/174332		10/2017
WO	WO 2018/077872		5/2018
WO	WO-2019020550	A2	1/2019
ZA	9605526	B	2/1997

OTHER PUBLICATIONS

International Preliminary Report on Patentability for Application No. PCT/EP2017/077154, dated May 9, 2019, 8 pages.

International Preliminary Report on Patentability for Application No. PCT/GB2012/000587, dated Jan. 23, 2014, 12 pages.

International Search Report and Written Opinion for Application No. PCT/GB2012/000587, dated Oct. 8, 2013, 17 pages.

KCI Licensing Inc, "Prevena™ Incision Management System—Clinician Guide—Instructions for Use," 390061 Rev D, Jan. 2010, 10 pages.

KCI Licensing Inc, "Prevena™ Incision Management System—Clinician Guide—Instructions for Use," 390153-WEB Rev B, Jan. 2010, 12 pages.

KCI Licensing, "Prevena™ Incision Management System—Patient Guide", 390064 Rev D, Jan. 2010, 4 pages.

KCI Licensing, "Prevena™ Incision Management System—Patient Guide," 390152-WEB C, Jan. 2011, 6 pages.

KCI Licensing, Prevena™ Incision Management System, Jun. 22, 2010, in 2 pages.

Notice of Opposition—Statement of Facts and Evidence for the European Patent No. 2731564, mailed Jan. 22, 2020, 12 pages.

Smith & Nephew, Allevyn Gentle Border Multisite, Jun. 2011, 2 pages.

Smith and Nephew Inc., "Allevyn Wound Dressings Pamphlet," 2008, 2 pages.

International Search Report and Written Opinion, re PCT Application No. PCT/EP2017/077154, dated Dec. 1, 2017.

\* cited by examiner




Fig. 1




Fig. 2




Fig. 3A





Fig. 3B



**Fig. 4**




Fig. 5




Fig. 6






Fig. 7

1

## MULTI-LAYERED WOUND DRESSING AND METHOD OF MANUFACTURE

### CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a U.S. national stage application of International Patent Application No. PCT/EP2017/077154, filed on Oct. 24, 2017, which claims priority to GB Application No. 1618298.2, filed Oct. 28, 2016, entitled MULTI-LAYERED WOUND DRESSING AND METHOD OF MANUFACTURE.

### BACKGROUND

#### Field

The present invention relates to a multi-layered wound dressing and a method of manufacturing such a wound dressing. In particular, but not exclusively, embodiments of the present invention relate to a multi-layered wound dressing having a fibrous absorbent layer that can resist shrinkage even under extreme sterilisation methods and storage conditions, have improved aesthetics and mechanical strength and thereby increase consistency of product over its shelf life.

#### Description of the Related Art

Wound dressings can be formed with a liquid-impermeable top layer (outer layer, furthest from the wound), which prevents wound exudates striking through and leaking from the dressing. The top layer is often also gas permeable and liquid vapour permeable, to help minimise maceration to the wound.

In some known wound dressings, the liquid-impermeable top layer can be susceptible to wrinkling (wrinkling includes but is not limited to inconsistent appearance, crinkles, creases textured surface). Wrinkling may occur whilst the wound dressing is packaged in a sterile packaging, and may be due to shrinking of one or more wound dressing layers over time. This may be due to the type of packaging and sterilisation method chosen. It could be perceived by a medical practitioner that if wrinkling is present the product has been compromised. Thus, it may not be possible to determine whether the wound dressing is still suitable for use. Wrinkling of the top layer may also occur whilst the wound dressing is in use. A wrinkled wound dressing is also visually unappealing to a patient.

Wound dressings often require a product shelf life of as long as possible, typically 5 years, so it is desirable to produce a wound dressing in which the liquid impermeable top layer is not as likely to wrinkle, become inconsistent in appearance or change aesthetics over time.

EP 1,314,410 discloses a multi-layered wound dressing having top film layer, but does not disclose any way of reducing or preventing shrinkage or wrinkling of the dressing.

### SUMMARY

According to a first aspect of the present invention there is provided a multi-layered wound dressing comprising:  
a fibrous absorbent layer for absorbing exudate from a wound site; and  
a support layer configured to reduce shrinkage of at least a portion of the wound dressing.

2

According to a second aspect of the present invention there is provided a method of manufacturing a multi-layered wound dressing, the method comprising:

forming a support layer;

5 forming a fibrous absorbent layer for absorbing exudate from a wound site; and

laminating the support layer and the absorbent layer together to form the wound dressing;

10 wherein the support layer is configured to reduce shrinkage of at least a portion of the wound dressing.

According to a third aspect of the present invention there is provided a method of treating a wound comprising placing a multi-layered wound dressing according to any embodiment disclosed herein over a wound.

15 According to a fourth aspect of the present invention there is provided a method of providing negative pressure wound therapy to a wound, the method comprising:

placing a multi-layered wound dressing according to any embodiment disclosed herein over a wound;

20 forming a fluid flow path between the wound dressing and a negative pressure source; and

operating the negative pressure source to provide negative pressure to the wound.

25 According to a fifth aspect of the present invention there is provided a method of operating a negative pressure wound system, the method comprising:

operating a negative pressure source fluidically connected to a multi-layered wound dressing according to any embodiment disclosed herein, the wound dressing configured to be positioned over a wound.

30 According to a sixth aspect of the present invention there is provided a negative pressure wound therapy kit comprising a multi-layered wound dressing according to any embodiment disclosed herein and a negative pressure source configured to be fluidically connected to the wound dressing.

35 According to another aspect there is provided a multi-layered wound dressing comprising:

40 a fibrous absorbent layer for absorbing exudate from a wound site; and

a support layer configured to reduce shrinkage of at least a portion of the wound dressing,

45 wherein the support layer comprises a net, the net comprises a geometric structure having a plurality of substantially geometric apertures extending therethrough; and

the geometric structure comprises a plurality of bosses substantially evenly spaced and joined by polymer strands to form the substantially geometric apertures between the polymer strands.

50 According to another aspect there is provided a multi-layered wound dressing comprising:

a fibrous absorbent layer for absorbing exudate from a wound site; and

55 a support layer configured to reduce shrinkage of at least a portion of the wound dressing,

wherein the net is formed from high density polyethylene.

According to another aspect there is provided a multi-layered wound dressing comprising:

60 a fibrous absorbent layer for absorbing exudate from a wound site; and

a support layer configured to reduce shrinkage of at least a portion of the wound dressing,

65 wherein the support layer has a tensile strength from 0.05 to 0.06 Nm.

According to another aspect there is provided a multi-layered wound dressing comprising:



a fibrous absorbent layer for absorbing exudate from a wound site; and

a support layer configured to reduce shrinkage of at least a portion of the wound dressing,

wherein the support layer is bonded to fibres in a top surface of the absorbent layer,

the support layer further comprises a bonding layer, wherein the support layer is heat laminated to the fibres in the absorbent layer via the bonding layer; and

wherein the bonding layer comprises a low melting point ethylene-vinyl acetate adhesive.

Certain embodiments of the invention provide the advantage that at least part of the wound dressing is less likely to shrink over time compared to known wound dressings.

Certain aspects of the invention provide a wound dressing in which wrinkling in a layer or layers of a wound dressing, e.g. a liquid impermeable film layer is prevented or reduced.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the invention are further described hereinafter with reference to the accompanying drawings, in which:

FIG. 1 is a schematic diagram of a section of an example of a wound dressing;

FIG. 2 is a schematic diagram of an example of a support layer;

FIG. 3A is a schematic diagram of a section of another example of a wound dressing;

FIG. 3B is a perspective view of the wound dressing of FIG. 3A;

FIG. 4 is a flow diagram of an example of a method of manufacturing the wound dressing of FIG. 3A;

FIG. 5 is a schematic diagram of a further example of a wound dressing; and

FIG. 6 is a schematic diagram of a yet further example of a wound dressing.

FIG. 7 is a schematic diagram of an example of a negative pressure wound therapy system.

In the drawings like reference numerals refer to like parts.

FIG. 1 shows an example of a multi-layer wound dressing 100. The wound dressing 100 includes a liquid impermeable film layer 102 located at the top of the wound dressing 100. In use, the film layer 102 is the top layer of the wound dressing 100, most distal from a wound site.

The film layer 102 is also gas and vapour permeable to allow for evaporation of fluid or wound exudate from the wound dressing 100, and help prevent maceration of the wound. In this example, the film layer 102 is formed from a polyurethane blend, though other suitable materials may include other polymeric materials, for example polyethylene, or polypropylene.

An absorbent layer 108 underlies the film layer 102. The absorbent layer 108 has a fibrous structure for absorbing exudate from a wound site. In this example, the absorbent layer 108 includes superabsorbent fibres. The absorbent layer 108 also includes other fibres. In this example, the absorbent layer includes superabsorbent fibres, viscose fibres and polyester fibres.

In this example, the absorbent layer 108 includes around 40% superabsorbent fibres, 40% viscose fibres, and 20% polyester fibres. In other examples, the absorbent layer may include around 0-50% superabsorbent fibres, 0-100% viscose fibres and 0-50% polyester fibres. Suitable superabsorbent fibres include crosslinked acrylate copolymer fibres that are partially neutralized to sodium salt however other superabsorbent fibres are available. The absorbent layer 108 may

be manufactured using a needling process in which the fibres are mechanically tangled together.

In other examples, the absorbent layer may include other ratios of superabsorbent, viscose and polyester fibres. For example, the absorbent layer may include around 50% superabsorbent fibres, 35% viscose fibres and 20% polyester fibres. Alternatively, the absorbent layer may include 40% superabsorbent fibres and 60% viscose fibres.

The film layer 102 is located over the absorbent layer 108 so that wound exudate collected in the absorbent layer 108 can evaporate out of the wound dressing 100 through the film layer 102.

A support layer 106 is located between the film layer 102 and the absorbent layer 108. The support layer 106 helps to reinforce the structure of the absorbent layer 108 and thereby reduce shrinkage of the wound dressing 100. The support layer 106 also helps to provide extra mechanical strength to the film layer 102 to reduce or prevent wrinkling of the film layer 102 over time. The mechanical strength also reduces the chance of the dressing deforming or rolling up causing a pressure point.

Aptly, the support layer 106 is configured to have a tensile strength from 0.05 to 0.06 Nm to provide mechanical strength to the surrounding layers (e.g. the film layer 102 and the absorbent layer 108) without compromising the flexibility of the wound dressing 100. The support layer 106 may have a thickness of from 50 to 150  $\mu\text{m}$ . Aptly, the support layer 106 may have a thickness of around 100 to 110  $\mu\text{m}$ .

Referring to FIG. 2, the support layer 106 includes a net 200 configured to reduce shrinkage of the wound dressing 100. Aptly, the net 200 is configured to reduce shrinkage of the absorbent layer 108 and/or the film layer 102 to help reduce wrinkling of the film layer 102.

In this example, the net 200 has a substantially hexagonal (or honeycomb) structure 204 including a plurality of substantially triangular shaped apertures 202 extending there-through.

The hexagonal structure 204 is formed from a plurality of dots (or bosses) 206 joined by polymer strands 208. The dots 206 are substantially evenly spaced with respect to each other. Each dot forms a vertex of the hexagonal pattern in the structure 204. Each dot 206 is joined to six surrounding dots 206 by polymer strands 208. That is, six polymer strands 208 extend from each dot 206 and each connect to a respective surrounding dot 206 to form the hexagonal structure 204 having triangular shaped apertures 202 between the polymer strands 208.

Each of the triangular shaped apertures 202 may have an area A of from 0.005 to 0.32  $\text{mm}^2$ . This allows liquid vapour from a wound to pass freely through the apertures, whilst still providing sufficient strength to the support layer 106.

It can also be said that the structure 204 is a structure comprising a plurality of strands or struts that are joined to form a plurality of triangles. In this example the triangles tessellate in rows. It will be appreciated that the strands or struts may be arranged in other formations, for example squares, diamonds or rectangles with different geometries and therefore differing open areas.

In this example, the support layer 106 is located directly adjacent the absorbent layer 108. As such, the support layer 106 can effectively provide additional mechanical strength to fibres in the top surface of the absorbent layer 108. This can help prevent movement of the fibres and reduce shrinking of the absorbent layer 108.

Aptly, the support layer 106 is bonded to the fibres in the top surface of the absorbent layer 108. This can help to lock the fibres in position and prevent or reduce any movement.



## 5

In this example, the support layer **106** further includes a bonding layer for heat laminating the net **200** to the absorbent layer **108**. The support layer **106** is thus heat laminated to fibres in the absorbent layer **108** via the bonding layer.

The bonding layer contained within the net has a lower melting temperature than the net **200** so that the support layer **106** can be heat laminated to the absorbent layer **108** whilst maintaining the structure of the net **200**. The bonding layer can be formed from a low melting point polymer, for example a low melting point ethylene-vinyl acetate, whilst the net **200** may be formed from a high density polyethylene, which melts at a higher temperature than the bonding layer. Other polymers having a lower melting point than the net **200** may also be suitable. For example the bonding layer may be a separate layer or alternatively include an ethylene-acrylate or thermoplastic polyurethane based adhesive.

The net **200** and the bonding layer can be coextruded to form the support layer **106**. Aptly, the bonding layer is extruded with a similar structural shape to the net **200**, so that the apertures **202** in the net **200** are not obstructed by the bonding layer. This helps to ensure that exudate the absorbent layer **108** can pass through the support layer and evaporate out of the wound dressing **100** through the film layer **102**.

FIG. **3** illustrates another example of a multi-layered wound dressing **300**. The wound dressing **300** includes a film layer **302**, support layer **306** and absorbent layer **308**, the same as the film layer **102**, support layer **106** and absorbent layer **108** described in relation to FIG. **1**.

The wound dressing **300** also includes a first adhesive layer **304**, located between the film layer **302** and the support layer **306**, for attaching the film layer **302** to the support layer **306**. The first adhesive layer **304** is a hot melt adhesive applied to a wound facing side (underside) of the film layer **302**. Aptly, the first adhesive layer **304** is pattern coated onto the film layer **302**, to include holes, so that gas and liquid vapour can pass through holes in the first adhesive layer **304**. In other examples the film layer **302** may be laminated (e.g. heat laminated) directly onto the support layer **306** without the need for an adhesive layer **304** in between.

In this example, the wound dressing **300** also includes a foam layer **312**, which is a fluid transport layer. The foam layer **312** is located under the absorbent layer **306**. The foam layer **312** acts to draw fluid away from a wound site and transport the fluid to the absorbent layer **308**. The foam layer may be formed from an open cell polyurethane foam and other options are available, as will be recognised by those skilled in the art.

An adhesive web layer **310** is located between the foam layer **312** and the absorbent layer **308** to adhere the foam layer **312** to the absorbent layer **308**. The adhesive web layer may be formed from bicomponent polypropylene/polyethylene fibres. Such bicomponent fibres are known in the art, so for brevity will not be discussed in detail. The adhesive web layer **310** includes a plurality of apertures extending therethrough to allow for passage of exudate from the foam layer **312** to the absorbent layer **108**.

The wound dressing **300** also includes a wound contact layer **320**, which includes a perforated film **316**. The perforated film **316** is located under the foam layer **312** and helps to prevent the wound dressing **300** from attaching to the wound as the wound heals. For example, where the wound dressing **300** includes the foam layer **312**, the perforated film **316** can prevent new tissue from growing into cells of the foam layer **312**. In other examples, the foam layer **312** may not be present and the perforated film **316** can help prevent fibres of the absorbent layer **308** from becoming

## 6

embedded in the wound. Perforations in the perforated film **316** are aptly substantially uniformly distributed and are of suitable size to allow passage of exudate into the wound dressing **300**, e.g. with holes having a diameter of 1-2.5 mm.

The perforated film **316** is aptly formed from polyurethane.

The wound contact layer **320** may also include an adhesive **318** located under the perforated film **316** (i.e. on the wound facing side of the perforated film **316**) for adhering the wound dressing **300** to the skin. In this case the adhesive is silicone **318** and is aptly spread onto the underside of the perforated film with a coat weight of around 30-200 g/m<sup>2</sup>. In some other examples, an additional attachment element, for example bandages, strips of tape, or compression bandages may be used to secure the wound dressing **300** to the patient.

The top side of the perforated film **316** (i.e. the side distal from the wound) may be coated with a further adhesive layer **314**. The further adhesive layer **314** adheres the wound contact layer **320** to the foam layer **312**. Aptly, the further adhesive layer **314** may be an acrylic adhesive, though other suitable adhesives may also be used. In other examples the wound contact layer **320** may be laminated (e.g. heat laminated) directly to the foam layer **312**, without the need for the further adhesive layer **314** in between.

FIG. **4** illustrates an example of a method of manufacturing the wound dressing **300**. The method is not limited to the steps shown and, as described above, may include additional steps. The method also is not limited to the order shown in FIG. **4**. As will be appreciated by those skilled in the art, several of the method steps shown may be performed in a different order. In some embodiments, the wound dressing **300** is manufactured by forming each of the layers, and assembling the layers in the correct order, before heat laminating them together.

The film layer **302** may be formed by extrusion. At step **401**, the first adhesive layer **304** is applied to the film layer. Aptly, the first adhesive layer **304** is pattern coated onto the underside of the extruded film layer **302**.

At step **402** the support layer **306** and the absorbent layer **308** are heat laminated together to form a single piece. At step **403** the film layer **302** and first adhesive layer **304** are heat laminated to the support layer **306** on the top side of the single piece and the adhesive web layer **310** and foam layer **312** are heat laminated to the absorbent layer **308**. Whilst the layers have been described as being heat laminated together in a specific order, the layers may be separately laminated together or laminated together all at the same time.

At step **404** the wound contact layer **320** is formed by coating one side of a film layer with the silicone adhesive layer **314**, and coating the other side of the film layer with a further adhesive layer **314**. The film layer is then perforated at step **405** (e.g. by needle punching), to form the wound contact layer **320** including the perforated film **316**, the silicone adhesive layer **314** for contacting the wound and the further adhesive layer **314**. Alternatively, the film layer may be perforated before adding the further adhesive layer **314**.

The wound contact layer may then be laminated (e.g. with heat, ultrasonic and/or radio frequency welding) to the underside of the foam layer **312** to form the wound dressing **300**, as shown at step **406**.

At step **407** a removable cover may be applied to the underside of the silicone adhesive layer **318**. This cover can be removed before the wound dressing **300** is applied to a patient.

At step **408** the wound dressing **300** may be cut into separate wound dressing pieces, each suitably sized for an intended application.



In another example, as shown in FIG. 5, the film layer 502 may have a larger surface area than the remainder of the wound dressing 500 so that it extends further outwardly than the other layers of the wound dressing. The wound-facing (underside) of the film layer may be coated with a pressure sensitive adhesive 504 (or other suitable adhesive) for sticking the dressing to the patient around the wound periphery. The pressure sensitive adhesive 504 may also adhere the film layer 502 to the support layer 506 of the wound dressing 500. The wound dressing may also include an absorbent layer 508, adhesive web layer 510, foam layer 512, further adhesive layer 514 and wound contact layer 520. Each of the layers in this example may be similar to corresponding layers described above in relation to FIGS. 3A and 3B, so for brevity will not be described again in detail.

In this example, the wound dressing may be manufactured following steps 401 to 407 described above. However, instead of cutting the dressing to size (step 408) each wound dressing may be made individually with each layer cut or formed to the desired size prior to laminating all the layers together so that the final wound dressing has a film layer larger than the other layers.

In a further example, as shown in FIG. 6, both the wound contact layer 620 and the film layer 602 may extend beyond the remaining layers of the wound dressing 600. The wound contact layer 620 and the film layer may be adhered together around the periphery (e.g. via an adhesive layer 604), so that the remaining layers of the wound dressing are sandwiched between the wound contact layer 620 and the film layer 602. In other words the support layer 606, the absorbent layer 608, the adhesive web layer 610, and the foam layer 612 may be sealed within a cavity 622 between the film layer 602 and the wound contact layer 620. In this example, a further adhesive layer 614 adheres the foam layer 612 to the wound contact layer 620, though in other examples the further adhesive layer 614 may not be required. Each of the layers in this example may be similar to corresponding layers described above in relation to FIGS. 3A and 3B, so for brevity will not be described again in detail.

The wound dressing 600 in this example may be manufactured similarly to the wound dressing 300, as described above, but with the film layer 602 and the wound contact layer 620 being laminated together around the periphery (e.g. via the adhesive layer 604) to sandwich the remaining layers between the film layer 602 and the wound contact layer 620. Alternatively, the film layer 602 may be directly laminated around the periphery (e.g. heat laminated) to the wound contact layer 620, without the need for the additional adhesive layer 604.

Although the wound dressings 300, 500, 600 have been described having several adhesive layers, one or more of these layers may not be present. For example, the perforated film itself may be formed from a hot melt adhesive material so that it can be directly heat laminated onto the foam layer, in which case the further adhesive layer may not be needed. In another example, the adhesive web layer may not be present if the foam and absorbent layers are adhered in another way. For example, the foam and absorbent layers may be directly chemically bonded together. Similarly, the first adhesive layer may not be needed. For example if the support layer includes an adhesive material, or if the film layer itself is formed from a hot melt adhesive then the film layer and the support layer may be directly adhered together.

In another example, the wound dressing may be provided without the foam layer. The foam layer helps to transport exudate away from the wound. However in some cases, and

depending on the severity of a wound, the absorbent layer may sufficiently draw exudate from the wound without the need for the foam layer.

Although in the examples described above, the support layer is heat laminated to the absorbent layer via a bonding layer, other laminating techniques may be suitable. For example, the bonding layer may include a pressure sensitive adhesive. In this case, heat may not be required to laminate the support layer and adhesive layer together.

Although in the example described above, the net layer has been described as having a substantially hexagonal shaped structure, other geometric structures may also be suitable.

With other geometric structures, the apertures may also have different geometric shapes.

In another example, the wound dressing may include more than one support layer to provide support to other layers in the wound dressing. For example a first support layer may be located between the liquid impermeable film layer and the absorbent layer, and a further support layer may be located between the absorbent layer and the fluid transport layer (foam layer). This may help to support the absorbent layer from both sides to further reduce shrinking of the absorbent layer.

Any of the examples described herein may be adapted for use with a negative pressure system (sometimes referred to as a reduced pressure system) including a source of negative pressure, such as a negative pressure pump. For example, the film layer may include a negative pressure interface, such as a port, to which a negative pressure supply tube may be connected. The supply tube may be connected to a negative pressure source so that, in use, the negative pressure source applies a negative pressure to the wound dressing between the film layer and the wound to help draw wound exudate away from the wound and into the absorbent layer of the dressing.

FIG. 7 illustrates an example of a negative pressure wound therapy system 700. The system includes a wound cavity 710 covered by a wound dressing 720, which can be a dressing according to any of the examples described herein. The dressing 720 can be positioned inside the wound cavity 710 and further seal the wound cavity so that negative pressure can be maintained in the wound cavity. For example, a film layer of the wound dressing 720 can provide substantially fluid impermeable seal over the wound cavity 710. A single or multi lumen tube or conduit 740 connects the wound dressing 720 with a negative pressure device 750 configured to supply reduced pressure. The negative pressure device 750 includes a negative pressure source. The negative pressure device 750 can be a canisterless device (meaning that exudate is collected in the wound dressing and/or is transferred via the tube 740 for collection to another location). In some embodiments, the negative pressure device 750 can be configured to include or support a canister. Additionally, in any of the embodiments disclosed herein, the negative pressure device 750 can be fully or partially embedded in, mounted to, or supported by the wound dressing 720.

The conduit 740 can be any suitable article configured to provide at least a substantially sealed fluid flow path or pathway between the negative pressure device 750 and the wound cavity 710 so as to supply reduced pressure to the wound cavity. The conduit 740 can be formed from polyurethane, PVC, nylon, polyethylene, silicone, or any other suitable rigid or flexible material. In some embodiments, the wound dressing 720 can have a port configured to receive an end of the conduit 740. For example, a port can include a



hole in the film layer. In some embodiments, the conduit **740** can otherwise pass through and/or under a film layer of the wound dressing **720** to supply reduced pressure to the wound cavity **710** so as to maintain a desired level of reduced pressure in the wound cavity. In some embodi-  
5 ments, at least a part of the conduit **740** is integral with or attached to the wound dressing **720**.

In use, the wound dressing, such as the wound dressing **100**, **300**, **500**, or **600**, is applied to a wound site with the wound contact layer **320** contacting the wound. Exudate  
10 from the wound may pass through the perforated film **116** and into the foam layer **312**, which acts to transport wound exudate away from the wound into the absorbent layer **308**. Wound exudate collected in the absorbent layer **308** can evaporate from the wound dressing **300** through the vapour  
15 permeable film layer **302**.

The support layer helps to provide mechanical strength to the absorbent layer, which may swell when it is wet and may shrink as it dries. The support layer can help to minimise movement of fibres in the absorbent layer at least on the side  
20 distal from the wound and thus helps to prevent shrinking of the wound dressing, particularly in this region. Minimising shrinking of the wound dressing in this way can in turn help to prevent wrinkling of the film layer. It also reduced the chance of the dressing rolling/folding up under secondary retention.

As the wound dressing becomes exposed to moisture (either from the wound or the surrounding atmosphere), it may swell or expand causing increased wrinkling of the film layer. Having the support layer adhered to the film layer can help to provide support to the film layer and resist wrinkling  
30 of the film layer by providing additional mechanical strength to the film layer.

The above described wound dressings are less likely to exhibit shrinking whilst stored in sterile packaging than previously known wound dressings. Thus, wrinkling of the film layer on the outside of the wound dressing can be prevented or reduced. A medical practitioner is therefore less likely to disregard a wound dressing that is still within its recommended shelf life, sterile and suitable for use, purely  
35 because of visual appearance of the film layer.

The hexagonal and/or triangular shape of the net structure of the support layer helps to provide mechanical strength and can be particularly effective at resisting against shrinkage of surrounding wound dressing layers.

Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of them mean “including but not limited to”, and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps. Throughout the description  
40 and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.

Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.  
45 All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclu-  
50 sive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel

one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so  
5 disclosed.

The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated  
10 herein by reference.

The invention claimed is:

**1.** A multi-layered wound dressing comprising:

a fibrous absorbent layer for absorbing exudate from a wound site;

a support layer configured to reduce shrinkage of at least a portion of the multi-layered wound dressing; and  
15 a liquid impermeable film layer,

wherein the support layer is located between the absorbent layer and the film layer, and  
20 wherein the support layer has a tensile strength from 0.05 to 0.06 Nm.

**2.** A multi-layered wound dressing according to claim **1**, wherein the support layer comprises a net.

**3.** A multi-layered wound dressing according to claim **2**, wherein the net comprises a geometric structure having a plurality of substantially geometric apertures extending  
25 therethrough.

**4.** A multi-layered wound dressing according to claim **3**, wherein the geometric structure comprises a plurality of bosses substantially evenly spaced and joined by polymer strands to form the plurality of substantially geometric apertures between the polymer strands.  
30

**5.** A multi-layered wound dressing according to claim **4**, wherein the geometric structure of the net comprises a hexagonal structure, and wherein the plurality of substantially geometric apertures have triangular shape.  
35

**6.** A multi-layered wound dressing according to claim **5**, wherein a boss of the plurality of bosses form a vertex of the hexagonal structure with polymer strands extending from the boss and connecting the boss to neighboring bosses, and wherein the plurality of substantially geometric apertures are formed between neighboring polymer strands.  
40

**7.** A multi-layered wound dressing according to claim **2**, wherein the net is formed from high density polyethylene.  
45

**8.** A multi-layered wound dressing according to claim **3**, wherein the plurality of substantially geometric apertures have an area from 0.005 to 0.32 mm<sup>2</sup>.  
50

**9.** A multi-layered wound dressing according to claim **1**, wherein the support layer has a thickness of from 50 to 150 μm.  
55

**10.** A multi-layered wound dressing according to claim **1**, wherein the support layer is located directly adjacent the absorbent layer.

**11.** A multi-layered wound dressing according to claim **1**, wherein the support layer is bonded to fibres in a top surface of the absorbent layer.

**12.** A multi-layered wound dressing according to claim **11**, wherein the support layer further comprises a bonding layer, wherein the support layer is heat laminated to the fibres in the absorbent layer via the bonding layer.  
60

**13.** A multi-layered wound dressing according to claim **12**, wherein the bonding layer comprises a low melting point ethylene-vinyl acetate adhesive, and wherein the support layer comprises a net formed from a material with a higher melting temperature than that of the bonding layer.  
65



**11**

**14.** A multi-layered wound dressing according to claim **1**, further comprising an adhesive layer attaching the film layer to the support layer.

**15.** A multi-layered wound dressing according to claim **1**, further comprising a wound contact layer located adjacent the absorbent layer for positioning adjacent a wound.

**16.** A multi-layered wound dressing according claim **15**, further comprising a fluid transport layer between the wound contact layer and the absorbent layer for transporting exudate away from a wound into the absorbent layer.

**17.** A method of treating a wound comprising placing a multi-layered wound dressing according to claim **1** over a wound.

**18.** A method of manufacturing a multi-layered wound dressing, the method comprising:

forming a support layer that comprises a net layer and a bonding layer by coextruding the net layer and the bonding layer;

forming a fibrous absorbent layer for absorbing exudate from a wound site; and

laminating the support layer and the absorbent layer together to form the wound dressing by attaching the bonding layer to the absorbent layer;

**12**

wherein the support layer is configured to reduce shrinkage of at least a portion of the multi-layered wound dressing, and

wherein the support layer has a tensile strength from 0.05 to 0.06 Nm.

**19.** A method according to claim **18**, wherein the bonding layer is formed from a polymer with a first melting temperature and the net layer is formed from a material with a second melting temperature higher than the first melting temperature of the polymer of the bonding layer, and wherein laminating the support layer and the absorbent layer comprises laminating by using heat so that the net layer maintains its structure during application of heat.

**20.** A method according to claim **18**, further comprising heat laminating the support layer to fibres in the absorbent layer via the bonding layer, wherein the bonding layer comprises a low melting point ethylene-vinyl acetate adhesive, and wherein the support layer comprises a net formed from a material with a higher melting temperature than that of the bonding layer.

\* \* \* \* \*

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 11,559,437 B2  
APPLICATION NO. : 16/345196  
DATED : January 24, 2023  
INVENTOR(S) : Daniel Lee Steward

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specification

Column 3, Line 41, below "In the drawings like reference numerals refer to like parts." insert -- DETAILED DESCRIPTION --, as a new heading.

Column 8, Line 14-15, delete "With other geometric structures, the apertures may also have different geometric shapes." and insert the same on Column 8, Line 13 as a continuation of the same paragraph.

In the Claims

Column 11, Line 7, in Claim 16, after "according" insert -- to --.

Signed and Sealed this  
Fourth Day of April, 2023



Katherine Kelly Vidal  
*Director of the United States Patent and Trademark Office*